Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting
Abstract Objective Ondansetron orally soluble pellicle can serve as an alternative option for preventing nausea and vomiting in patients who receive chemotherapy. However, there is a lack of clinical evidence regarding ondansetron. This study aimed to explore the efficacy and safety of ondansetron i...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13406-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544514459664384 |
|---|---|
| author | Lu Sun Jia Ma Yajuan Zhou Xiaofang Ying Gai Liang Guoliang Pi Ying Li Yan Luo Jianping Bi Hanping He Yi Peng |
| author_facet | Lu Sun Jia Ma Yajuan Zhou Xiaofang Ying Gai Liang Guoliang Pi Ying Li Yan Luo Jianping Bi Hanping He Yi Peng |
| author_sort | Lu Sun |
| collection | DOAJ |
| description | Abstract Objective Ondansetron orally soluble pellicle can serve as an alternative option for preventing nausea and vomiting in patients who receive chemotherapy. However, there is a lack of clinical evidence regarding ondansetron. This study aimed to explore the efficacy and safety of ondansetron in patients with malignant tumours who received chemotherapy drugs with a moderate-to-high emetic risk. Methods In total, 163 patients with malignant tumours received 24 mg of ondansetron via orally soluble pellicles at 30 min before chemotherapy (8 mg each time for three consecutive administrations). The incidence rates of nausea and vomiting in the three days after chemotherapy were recorded. Results Regarding the effect of ondansetron on vomiting, the complete response (zero episodes of vomiting), major response (1–2 episodes of vomiting), minor response (3–5 episodes of vomiting), and failure (> 5 episodes of vomiting) rates were 96.9%, 1.2%, 1.2%, and 0%, respectively. The major efficacy rate for vomiting (complete response + major response rates) was 98.1%. Moreover, 96.3% of patients did not experience nausea, 2.5% of patients experienced mild nausea, 1.2% of patients experienced moderate nausea, and 0.0% of patients experienced severe nausea. The major efficacy rate for nausea (no nausea) was 96.3%. Age > 65 years was negatively associated with major efficacy for vomiting, and a chemotherapy regimen involving cisplatin was negatively associated with major efficacy for nausea. A total of 42 (25.8%) patients experienced adverse events. The most common adverse events were elevated levels of alanine transaminase (6.7%), elevated levels of aspartate transaminase (3.7%), fatigue (3.7%), and cough (2.5%). Conclusion Ondansetron orally soluble pellicle shows good antiemetic efficacy and high safety in patients with malignant tumours who receive chemotherapy drugs with a moderate-to-high emetic risk. |
| format | Article |
| id | doaj-art-6a982aed78e34e558ee94e9e5f07c7c9 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-6a982aed78e34e558ee94e9e5f07c7c92025-01-12T12:27:30ZengBMCBMC Cancer1471-24072025-01-012511910.1186/s12885-024-13406-zEfficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomitingLu Sun0Jia Ma1Yajuan Zhou2Xiaofang Ying3Gai Liang4Guoliang Pi5Ying Li6Yan Luo7Jianping Bi8Hanping He9Yi Peng10Department of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Objective Ondansetron orally soluble pellicle can serve as an alternative option for preventing nausea and vomiting in patients who receive chemotherapy. However, there is a lack of clinical evidence regarding ondansetron. This study aimed to explore the efficacy and safety of ondansetron in patients with malignant tumours who received chemotherapy drugs with a moderate-to-high emetic risk. Methods In total, 163 patients with malignant tumours received 24 mg of ondansetron via orally soluble pellicles at 30 min before chemotherapy (8 mg each time for three consecutive administrations). The incidence rates of nausea and vomiting in the three days after chemotherapy were recorded. Results Regarding the effect of ondansetron on vomiting, the complete response (zero episodes of vomiting), major response (1–2 episodes of vomiting), minor response (3–5 episodes of vomiting), and failure (> 5 episodes of vomiting) rates were 96.9%, 1.2%, 1.2%, and 0%, respectively. The major efficacy rate for vomiting (complete response + major response rates) was 98.1%. Moreover, 96.3% of patients did not experience nausea, 2.5% of patients experienced mild nausea, 1.2% of patients experienced moderate nausea, and 0.0% of patients experienced severe nausea. The major efficacy rate for nausea (no nausea) was 96.3%. Age > 65 years was negatively associated with major efficacy for vomiting, and a chemotherapy regimen involving cisplatin was negatively associated with major efficacy for nausea. A total of 42 (25.8%) patients experienced adverse events. The most common adverse events were elevated levels of alanine transaminase (6.7%), elevated levels of aspartate transaminase (3.7%), fatigue (3.7%), and cough (2.5%). Conclusion Ondansetron orally soluble pellicle shows good antiemetic efficacy and high safety in patients with malignant tumours who receive chemotherapy drugs with a moderate-to-high emetic risk.https://doi.org/10.1186/s12885-024-13406-zOndansetron orally soluble pellicleModerate-to-high emetic risk chemotherapyNausea and vomitingEfficacySafety |
| spellingShingle | Lu Sun Jia Ma Yajuan Zhou Xiaofang Ying Gai Liang Guoliang Pi Ying Li Yan Luo Jianping Bi Hanping He Yi Peng Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting BMC Cancer Ondansetron orally soluble pellicle Moderate-to-high emetic risk chemotherapy Nausea and vomiting Efficacy Safety |
| title | Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting |
| title_full | Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting |
| title_fullStr | Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting |
| title_full_unstemmed | Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting |
| title_short | Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting |
| title_sort | efficacy and safety of ondansetron orally soluble pellicle for preventing moderate to high emetic risk chemotherapy induced nausea and vomiting |
| topic | Ondansetron orally soluble pellicle Moderate-to-high emetic risk chemotherapy Nausea and vomiting Efficacy Safety |
| url | https://doi.org/10.1186/s12885-024-13406-z |
| work_keys_str_mv | AT lusun efficacyandsafetyofondansetronorallysolublepellicleforpreventingmoderatetohighemeticriskchemotherapyinducednauseaandvomiting AT jiama efficacyandsafetyofondansetronorallysolublepellicleforpreventingmoderatetohighemeticriskchemotherapyinducednauseaandvomiting AT yajuanzhou efficacyandsafetyofondansetronorallysolublepellicleforpreventingmoderatetohighemeticriskchemotherapyinducednauseaandvomiting AT xiaofangying efficacyandsafetyofondansetronorallysolublepellicleforpreventingmoderatetohighemeticriskchemotherapyinducednauseaandvomiting AT gailiang efficacyandsafetyofondansetronorallysolublepellicleforpreventingmoderatetohighemeticriskchemotherapyinducednauseaandvomiting AT guoliangpi efficacyandsafetyofondansetronorallysolublepellicleforpreventingmoderatetohighemeticriskchemotherapyinducednauseaandvomiting AT yingli efficacyandsafetyofondansetronorallysolublepellicleforpreventingmoderatetohighemeticriskchemotherapyinducednauseaandvomiting AT yanluo efficacyandsafetyofondansetronorallysolublepellicleforpreventingmoderatetohighemeticriskchemotherapyinducednauseaandvomiting AT jianpingbi efficacyandsafetyofondansetronorallysolublepellicleforpreventingmoderatetohighemeticriskchemotherapyinducednauseaandvomiting AT hanpinghe efficacyandsafetyofondansetronorallysolublepellicleforpreventingmoderatetohighemeticriskchemotherapyinducednauseaandvomiting AT yipeng efficacyandsafetyofondansetronorallysolublepellicleforpreventingmoderatetohighemeticriskchemotherapyinducednauseaandvomiting |